Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 11, 2015

View Archived Issues

Shionogi presents highlights of first quarter of fiscal 2015

Novel potent cross-reactive MAb that neutralizes influenza A virus

Novo Nordisk reviews second quarter 2015

New findings concerning the pathophysiology of spinal cord injury

Emergent BioSolutions plans to spin off immuno-oncology business

German and U.S. team presents omega-3 PUFA analogues

Allergan divulges prostanoid receptor antagonists

Piramal introduces EZH2 inhibitors

Daiichi Sankyo discloses LCAT activators

MabVax and Rockefeller University enter into research collaboration agreement

Inovio and MedImmune establish cancer vaccine collaboration

Anti-IL-23 therapy shows promise for the treatment of psoriasis

Sanofi, Evotec and Apeiron Biologics collaborate on development of immuno-oncology treatments

Phase I study investigates DNA vaccine pTVG-AR for metastatic prostate cancer

Merck & Co. divulges MGAT2 inhibitors

Cancer Research UK awards grant to Newcastle University's Northern Institute of Cancer Research

Sanofi files application for alirocumab approval in Japan

Torii and ALK's Japanese cedar pollen SLIT improves rhinitis symptoms in phase II/III trial

FDA grants orphan drug designation to recombinant IVIG-mimetic GL-2045

RegeneRx updates on clinical development of RGN-259

Antibe Therapeutics completes phase I development of ATB-346

SAGE Therapeutics and FDA agree design of phase III SAGE-547 trial under SPA

MJFF to fund preclinical study of ANAVEX 2-73 for Parkinson's disease

ProMetic Life Sciences completes first plasminogen dosing round in phase I trial

Turing acquires Daraprim U.S. rights from Impax

FDA approves Keveyis for primary hyperkalemic and hypokalemic periodic paralysis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...